ClinicalTrials.gg
Active, not recruitingNCT07178327Updated Sep 2, 2026

Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101

A Phase 1 interventional study of LYN101 and Placebo in Osteoporotic Fracture, sponsored by Shanghai TTM-Bio Technology Co., Ltd. Active, not recruiting at 2 sites in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Shanghai TTM-Bio Technology Co., Ltd · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Osteoporotic Fractures with a site in China — 7 open to participants now, 8 under way, none of them phase 3. Osteoporotic Fractures · China.

Started
2025
with 1 other
Phase 1
Only one
of the 13
Registered
13th of 13
by date
Lead sponsor
1 of 13
Shanghai TTM-Bio Technology Co., Ltd

Among the 13 studies in Osteoporotic Fractures with a site in China, this one is one of 2 that started in 2025, is the only one in phase 1, and was the 13th registered.

Osteoporotic Fractures

87 studies on the registry are indexed under Osteoporotic Fractures; 22 are open to participants now.

Browse Osteoporotic Fractures studies →

Open to participants now

7 of the 13 studies in Osteoporotic Fractures with a site in China are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 14 Osteoporotic Fractures studies recruiting now, 9 (64%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Osteoporotic Fractures with a site in China, or all of them as a file.
02

Study summary

This is a Phase 1, two-part, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of LYN101 in healthy subjects (part A) and multiple doses in postmenopausal women with low bone mass (part B).

Read the detailed description

The study includes Part A and Part B. Up to four dose levels will be tested in the single ascending dose stage, involving approximately 32 healthy volunteer subjects, with eight subjects per dose level (Part A). After completing Part A, one dose level or additional optional levels will be tested in multiple doses in Part B, enrolling about 32 postmenopausal women with low bone mass. In both Part A and Part B, eligible subjects will be randomized in a 3:1 ratio to receive either LYN101 or a matched placebo.

03

Conditions studied

  • Osteoporotic Fracture

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion Criteria for Part A:

  1. Fully understand the purpose and requirements of the trial, voluntarily participate in the clinical study, and sign a written form.
  2. Individuals aged 18 to 65 years (inclusive), regardless of gender;
  3. Weight ≥ 50 kg for males or at least 45 kg for females, with a (BMI) ranging from 18.0 to 30.0 kg/m² (inclusive).
  4. Males and females of agree not to plan for childbearing and to use reliable measures from the time of signing the written informed consent until 6 months after dosing. They also agree not to donate sperm or ova.

Inclusion Criteria for Part B:

  1. Fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial, and sign a written informed consent form.
  2. Individuals aged 50-70 years (inclusive), female, and ambulatory.
  3. Spontaneous amenorrhea lasting for at least two years or bilateral oophorectomy performed at least two years prior. For women under 60 years of age who have undergone hysterectomy but retained their ovaries, or when the status of bilateral oophorectomy is unknown, menopausal status must be confirmed by follicle-stimulating hormone (FSH) levels exceeding 40 mIU/mL or in accordance with the range established by the local laboratory.
  4. During the screening process, at least two consecutive vertebrae within the L1-L4 region must be evaluable for DXA BMD assessment, and at least one hip must also be evaluable for DXA BMD assessment.
  5. Low bone mass, as measured by Dual Energy X-ray Absorptiometry (DXA) during screening (BMD), shall meet the criteria if any site has a T-score less than -1.0 and greater than -2.5 at the lumbar spine L1-L4, femoral neck, or total hip.

Exclusion Criteria:

Exclusion Criteria for Part A:

  1. Systolic blood pressure (SBP) ≥140 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg after at least five minutes of rest during screening assessments.
  2. abnormalities observed in the 12-lead at screening include, but are not limited to, a Mean > 450 ms for males or > 470 ms for females. The measurement is taken while the subject is supine after resting for at least 10 minutes, with three readings obtained at intervals of at least 1 minute. If the mean QTcF exceeds these limits, the ECG measurement should be repeated three times. If the retest results are still abnormal, the subject is excluded.

    PR interval \< 120 ms PR interval > 200 ms

  3. Clinically significant abnormalities in laboratory tests, chest X-ray, and/or abdominal ultrasound at Screening unless the Investigator determines they are non-interfering.
  4. 25-hydroxyvitamin D3 concentration \< 20 ng/mL at screening and unwilling to supplement vitamin D.
  5. (AST), alanine aminotransferase (ALT), and/or total (TBIL) levels exceeding the (ULN) at screening.
  6. (INR) greater than 1.5 at screening.
  7. Corrected serum calcium and phosphorus levels outside the laboratory reference range at Screening (calcium and phosphorus supplements should not be taken for at least 8 hours before measuring serum calcium and phosphorus).
  8. Estimated \<60 mL/min (using the Cockcroft-Gault formula) at screening.
  9. Any disease that might impact the safety evaluation of the subject or the in vivo process of the product, including the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematopoietic system, metabolic endocrine system, and others.
  10. Participation in any other drug or device clinical trials within 30 days or five half-lives (whichever is longer) before screening.
  11. Use of prescription drugs within 14 days or five half-lives (whichever is longer) before administering the investigational product, unless the Investigator and Sponsor determine they are non-interfering (e.g., hormonal contraceptives).
  12. Use of over-the-counter (OTC) drugs within 7 days or five half-lives (whichever is longer) before administering the investigational product, unless the Investigator and Sponsor determine they are non-interfering.
  13. Test results show positive for the surface antigen (HBsAg), virus (HCV) antibody, Treponema pallidum antibody, or (HIV) antibody.
  14. Use of more than 10 sticks per day of tobacco or nicotine products within the past 30 days before screening.
  15. History of alcohol, drug, or substance abuse within the 12 months before screening.
  16. Known allergy to human immunoglobulins, the investigational product or its components, calcium preparations, or vitamin D preparations.
  17. Receiving a (excluding influenza vaccine) within 4 weeks before screening, or planning to receive a live vaccine during the study.
  18. Blood donation or blood loss of 400 mL or more within the past thirty days before screening.
  19. Pregnant or breastfeeding women.
  20. Any condition that, in the investigator's opinion, makes the subject unsuitable for enrollment or may interfere with the subject's participation or completion of the study.

Exclusion Criteria for Part B:

  1. Presence of bone metabolic diseases such as hypoparathyroidism, hyperparathyroidism, hypothyroidism, hyperthyroidism, hypopituitarism, hyperprolactinemia, Cushing's syndrome, acromegaly, Paget's disease, rheumatoid arthritis, osteomalacia, among others; individuals with stable hypothyroidism (for at least three months) on thyroid hormone replacement therapy may be eligible for enrollment, provided they meet the following criteria: a TSH level ranging from 4.0 to 10.0 μIU/mL and serum FT4 within the normal range.
  2. The following medications that may affect bone metabolism have been received: (≥ prednisone 5 mg/day or equivalent, taken for at least 10 consecutive days), vitamin K, calcitonin preparations, selective estrogen receptor modulators, sex hormone preparations (excluding vaginal tablets and creams for vaginal use), immunomodulatory agents (such as cyclosporine, tacrolimus, etc.), or methotrexate (excluding calcium and vitamin D supplements) within the past two months; alternatively, bisphosphonates used within the 12 months before screening or used continuously for more than one year within the last two years; or the use of parathyroid hormone (PTH) analogs, anti-RANK ligand (RANKL) antibodies, cathepsin K inhibitors, or anti-Sclerostin antibodies.
  3. 25-hydroxyvitamin D3 concentration \< 20 ng/mL at screening, except for those who agree to vitamin D supplementation to meet the requirement;
  4. Estimated creatinine clearance below 60 mL/min (Cockcroft-Gault formula) during screening.
  5. Corrected serum calcium levels were outside the laboratory reference range at screening. (Calcium preparations should not be taken for at least 8 hours before measuring serum calcium during screening.)
  6. Systolic blood pressure (SBP) is 140 mmHg or higher, and/or diastolic blood pressure (DBP) is 90 mmHg or higher, after at least five minutes of rest during screening.
  7. Mean QTcF >470 ms at Screening (measured supine after resting for at least 10 minutes, 3 times with at least 1 minute interval); If the mean QTcF exceeds this limit, repeat the 12-lead ECG measurement 3 times; if the results of the retest are still abnormal, the subject is excluded.
  8. Clinically significant cardiovascular, respiratory, digestive, dermatological, urinary, hematological, neurological, psychiatric, or other systemic diseases or laboratory abnormalities, and if the investigator determines the subject is unsuitable for participation.
  9. within the past 5 years (except completely resected in-situ basal cell or squamous cell skin cancer, cervical carcinoma in situ, or ductal carcinoma in situ of the breast).
  10. Known active tuberculosis.
  11. Positive for HBsAg, HCV antibody, HIV antibody, or Treponema pallidum antibody.
  12. Participation in any other drug or device clinical trials within 30 days or five half-lives (whichever is longer) before screening.
  13. Known prior use of humanized IgG antibodies.
  14. Known allergies to human immunoglobulins, the investigational product, its components, calcium supplements, or vitamin D supplements.
  15. Receiving a live vaccine (excluding influenza vaccine) within 4 weeks before screening, or planning to receive a live vaccine during the study.
  16. History of alcohol, drug, or substance abuse.
  17. Fragility fracture within six months before enrollment or when the Investigator considers subjects to be at high risk of fragility fracture requiring treatment with active medications (other than calcium and vitamin D supplements) (Fragility fracture: a fracture occurring under normal or minimal external force due to the inherent fragility of the bone).
  18. Any condition that, in the Investigator's opinion, makes the subject unsuitable for enrollment or may interfere with the subject's participation or completion of the study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    LYN101

    In part A, up to 4 single ascending dose cohorts. In part B, up to 4 multiple dose cohorts.

    Drug: LYN101

  • Placebo comparator
    Placebo

    Eligible participants will receive the matched placebo via SC injection.

    Drug: Placebo

Interventions

  • DrugLYN101

    In Part A, participants will receive single dose of LYN101 administered as a subcutaneous (SC) injection. In Part B, participants will receive multiple doses of LYN101 administered as a SC injection.

  • DrugPlacebo

    In Part A, participants will receive single dose of the matched placebo administered as a subcutaneous (SC) injection. In Part B, participants will receive multiple doses of the matched placebo administered as a SC injection.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    An AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related during study

    Time frame: Up to Day 91 from dosing in part A. Up to 175 from first dosing in part B.

Secondary outcomes

  1. Bone turnover markers

    The changes from baseline following LYN101 SC administration.

    Time frame: Up to Day 91 in part A. Up to 175 in part B.

  2. Peak serum concentration (Cmax)

    Cmax of LYN101.

    Time frame: UP to Day 91 in part A. Up to Day 175 in part B

  3. Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCtau) of LYN101

    AUCtau of LYN101.

    Time frame: Up to Day 91 in part A. Up to Day 175 in part B.

  4. Time to cmax (Tmax) of LYN101

    Tmax of LYN101

    Time frame: Up to Day 91 in part A. Up to Day 175 in part B.

  5. Observed plasma concentration at the end of a dosing interval (Ctrough) of LYN101

    Ctrough of LYN101

    Time frame: Up to Day 175 in part B.

  6. Terminal Phase Elimination Half-Life (t1/2) of LYN101

    T1/2 of LYN101.

    Time frame: Up to Day 91 in part A. Up to Day 175 in part B.

  7. Clearance (CL) for LYN101 SC

    CL for LYN101 SC.

    Time frame: Up to Day 91 in part A. Up to Day 175 in part B.

  8. Immunogenicity of LYN101 assessed by anti-drug antibodies (ADAs)

    Incidence and concentrations of ADAs. Neutralizing ADAs (NAb) may be evaluated.

    Time frame: Up to Day 91 in part A. Up to Day 175 in part B.

Other outcomes

  1. Bone mineral density

    The change from baseline after LYN101 or placebo administration

    Time frame: Up to Day 91 in part A. Up to Day 175 in part B

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartActual
Sep 6, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Mar 30, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07178327
Lead sponsor
Shanghai TTM-Bio Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Sep 6, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Huan Zhou
study director · The First Affiliated Hospital of Bengbu Medical University
Huan Zhou, Dr
principal investigator · The First Affiliated Hospital of Bengbu Medical University
Lin Zhen Zhang, Dr
principal investigator · Shanghai 6th People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion